RCD405

RCD405 is a novel small molecule drug candidate belonging to the quinoline class, developed primarily for the treatment of chronic obstructive pulmonary disease (COPD) and severe asthma. It is distinguished by its dual mechanism of action, exhibiting both bronchodilatory and anti-inflammatory effects. Preclinical studies have demonstrated that RCD405 induces airway relaxation comparable to standard-of-care bronchodilators such as formoterol and tiotropium in human tissue models. Additionally, it significantly reduces airway hyperresponsiveness (AHR), immune cell recruitment, proinflammatory cytokine expression (notably IL-4, IL-5, IL-13), and NF-κB activation in animal models of allergic asthma and LPS-induced inflammation. The compound appears to act via inhibition of mitochondrial oxidative phosphorylation complexes—leading to decreased cellular metabolic activity—and modulation of NF-κB–associated inflammatory pathways. RCD405 is being formulated as an inhaled dry powder for targeted delivery to the lungs[1][2][3][4][5][6][7][8][9].